[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100369112":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":55,"collaborators":19,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":19,"enrollmentInfo":67,"targetDuration":19,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":36,"whyStopped":19,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University of Sydney","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Markerless Image Guidance Arm","EXPERIMENTAL","Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging",[13],"Device: Markerless Image Guidance",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DEVICE","Markerless Image Guidance",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Paul Keall, PhD","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Trial Coordinator","CONTACT","+61 2 8627 1185","shona.silvester@sydney.edu.au",{"name":31,"role":27,"phone":28,"phoneExt":19,"email":32},"Research Student","Jonathan.Hindmarsh@sydney.edu.au",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Alfred Health","RECRUITING","Melbourne","Victoria","3004","Australia","AU",{"type":43,"coordinates":44},"Point",[45,46],144.96332,-37.814,{"lat":46,"lon":45},[49,53],{"name":50,"role":27,"phone":51,"phoneExt":19,"email":52},"Carole Owens","+61 3 90762174","c.owens@alfred.org.au",{"name":54,"role":23,"phone":19,"phoneExt":19,"email":19},"Sashendra Senthi, PhD",{"type":56,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100369112","markerless-image-guidance-using-intrafraction-kilovoltage-x-ray-imaging-100369112",false,"NCT04086082","Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging","MAGIK: Using Implanted Markers to Determine the Feasibility of Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging: A Phase I Interventional Study of Lung Cancer Radiotherapy","MAGIK","Inclusion Criteria:\n\n* Is willing to comply with all trial procedures and intends to provide written Informed Consent for participation in this trial.\n* Patients undergoing external beam radiotherapy.\n* Histologically proven Stage I NSCLC or oligometastatic lung metastases (3 or less).\n* MRI\u002F4D-CT prior to insertion of fiducial markers.\n* Patient must be able to have fiducial markers placed in the lung (if on anticoagulants, must be cleared by LMO or cardiologist).\n* ECOG performance status 0-2.\n* A maximum of three metastases to the lung from any non-haematological malignancy. Multiple metastases will be treated separately.\n* 1 cm ≤ Tumour diameter in any dimension ≤ = 5 cm.\n* The distance between the tumour centroid and the top end of the diaphragm is \\\u003C=10 cm.\n\nExclusion Criteria:\n\n* Patient has low respiratory performance as evaluated by the physicians.\n* Previous high-dose thoracic radiotherapy.\n* Less than one fiducial marker implanted in the lung.\n* Fiducial markers are too far from the tumour centroid (\\>9 cm).\n* Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently with treatment. Hormonal manipulation agents are allowable (e.g. aromatase inhibitors, selective oestrogen receptor modulators, and gonadotropin releasing hormone receptor modulators).\n* Targeted agents (such as sunitinib, bevacizumab and tarceva) within 7 days of commencement of treatment, or concurrently with treatment.\n* Women who are pregnant or lactating.\n* Unwilling or unable to complete quality of life questionnaires.","ALL","18 Years",{"count":68,"type":69},30,"ESTIMATED","INTERVENTIONAL",[72],"NA","This trial will investigate the feasibility of the Markerless Tumour Tracking technology.",[75],"Lung Cancer",[77,78,79],"Lung cancer","NSCLC","Oligometastases","2026-05-18",{"date":82,"type":83},"2026-05-20","ACTUAL",{"date":85,"type":83},"2023-05-24",{"date":87,"type":69},"2028-12",{"name":5,"class":6},1]